Insulin (Novo, Lilly, Sanofi)

Three companies supply nearly all the world's insulin, a life-sustaining molecule with no immediate substitute for hundreds of millions of diabetics. Biomanufacturing is complex and barely redundant; a plant failure or a commercial decision by one player affects access to treatment, above all in low-income countries.